Orchid Pharma Q4 FY26 Results: Net Profit ₹3060 Crore, Approves Internal Auditor Appointment
Orchid Pharma reported Q4 FY26 standalone net profit of ₹3,060.37 lakhs and consolidated net profit of ₹2,378.02 lakhs. The company's Board approved the FY26 audited financial results and appointed the Internal Auditor for FY27. Acquisitions of Allecra Therapeutics assets were completed, and an amalgamation scheme with Dhanuka Laboratories is pending NCLT approval.
The financial results, coupled with significant acquisition and ongoing amalgamation activities, are material to the company's future performance and strategic direction.
The results show a significant profit for the quarter, but the consolidated results have a modified opinion from auditors, and the amalgamation is still pending NCLT approval. The acquisition news is positive but balanced by these factors.
Orchid Pharma Limited announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company's Board of Directors, in a meeting held on May 25, 2026, approved these results, which include the statement of assets and liabilities and cash flow statement.
The Board also approved the appointment of the Internal Auditor for the Financial Year 2026-27. The statutory auditors issued an unmodified opinion on the standalone financial results and a modified opinion on the consolidated financial results.
For the quarter ended March 31, 2026, Orchid Pharma reported a net profit of ₹3,060.37 lakhs on standalone basis and ₹2,378.02 lakhs on a consolidated basis. For the full financial year ended March 31, 2026, the standalone net profit stood at ₹4,520.79 lakhs and consolidated net profit was ₹2,054.70 lakhs.
The company also provided an update on the amalgamation scheme with its holding company, Dhanuka Laboratories Limited, stating that the NCLT has reserved its order. Additionally, Orchid Pharma completed the acquisition of 100% assets of Allecra Therapeutics GmbH and Allecra Therapeutics SAS, securing full global ownership of Enmetazobactam (EXBLIFEP/Orblicef). A wholly-owned subsidiary, Orchid Pharma Europe GmbH, was also incorporated.
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.